JPMorgan Chase & Co. Boosts Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $18.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price lifted by JPMorgan Chase & Co. from $16.00 to $18.00 in a report released on Monday, Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities research analysts also recently weighed in on TEVA. Jefferies Financial Group raised their price target on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Wednesday, July 10th. Finally, UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Stock Down 0.9 %

TEVA stock opened at $18.25 on Monday. The company has a 50 day moving average of $18.02 and a two-hundred day moving average of $16.73. The company has a market cap of $20.67 billion, a price-to-earnings ratio of -44.50, a PEG ratio of 1.32 and a beta of 0.88. Teva Pharmaceutical Industries has a 12-month low of $8.10 and a 12-month high of $19.08. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The business had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. On average, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares of the company’s stock, valued at $777,285. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.55% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. GHP Investment Advisors Inc. grew its stake in shares of Teva Pharmaceutical Industries by 1,681.4% in the third quarter. GHP Investment Advisors Inc. now owns 32,065 shares of the company’s stock worth $578,000 after acquiring an additional 30,265 shares during the last quarter. Burford Brothers Inc. grew its position in Teva Pharmaceutical Industries by 3.8% in the 3rd quarter. Burford Brothers Inc. now owns 153,262 shares of the company’s stock worth $2,762,000 after purchasing an additional 5,618 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Teva Pharmaceutical Industries by 244.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,389,847 shares of the company’s stock worth $25,045,000 after purchasing an additional 985,845 shares during the last quarter. IFM Investors Pty Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 3.7% during the 3rd quarter. IFM Investors Pty Ltd now owns 231,028 shares of the company’s stock worth $4,163,000 after purchasing an additional 8,285 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its position in shares of Teva Pharmaceutical Industries by 7.2% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 310,116 shares of the company’s stock valued at $5,588,000 after buying an additional 20,837 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.